We are proud to announce that our distinguished hybrid / 505(b)(2) asset Gralise® has reached an advanced stage and that Adalvo will move into launch in Q1 2023. With this achievement we add a new milestone in creating Adalvo’s mission for a boutique portfolio containing high-value products, innovating and bringing new solutions for the partners and patients we serve. Adalvo is the exclusive owner of this asset for all ex-US regions which further underpins our differentiated portfolio strategy since this differentiated extended release profile is a complete innovation for the vast majority of markets ex-US.
Gralise® is a one-of-a-kind Gabapentin ER formulation that is originally marketed by our sister company Almatica in the US. Our brand is approved in the treatment of postherpetic neuralgia and offers significant patient convenience compared to traditional Gabapentin IR formulations. Apart of reduced pill-burden we offer readily available and proven medico-marketing materials to our partners. Gralise® is selling close to $100mio in the US, according to IQVIA.